Beqvez (previously Durveqtix)
Withdrawn
fidanacogene elaparvovec
Medicine
Human
Withdrawn
On 15 May 2025, the European Commission withdrew the marketing authorisation for Beqvez (fidanacogene elaparvovec) in the European Union (EU). The withdrawal was requested by the marketing authorisation holder, Pfizer Europe MA EEIG, due to commercial reasons.
Beqvez was granted conditional marketing authorisation in the EU on 24 July 2024 for the treatment of severe and moderately severe haemophilia B. The product had not been marketed in the EU.
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain: